|Study||Year∗||Trial Completion||Primary Study Endpoint||Trial Design and Outcome||Expected Event Rate in Control Group (%)||Observed Event Rate in Control Group (%)||Proportion With Newer-Generation DES (%)|
|DES LATE (12 vs. 36 mo) (13)||2010||Extension of ZEST-LATE and REAL-LATE (12)||Cardiac death, MI, or stroke <24 h||Superiority not shown||2.7||2.6||30|
|PRODIGY (6 vs. 24 mo) (14,15)||2012||Enrollment completed||Death, MI, or stroke||Superiority not shown||8.0||10.1||67|
|EXCELLENT (6 vs. 12 mo) (16)||2012||Enrollment completed||Cardiac death, MI, or ischemia-driven TVR||Noninferiority confirmed||10.0||4.5||75|
|RESET (3 vs. 12 mo) (17)||2012||Enrollment completed||Cardiac death, MI, ST, revasc, or bleeding||Noninferiority confirmed||10.5||4.7||85|
|OPTIMIZE (3 vs. 12 mo) (18)||2013||Enrollment completed||NACCE–death, MI, stroke, or bleed||Noninferiority confirmed||9.0||6.0||100|
|ARCTIC Interruption (12 vs. 18 mo) (19)||2014||Extension of ARCTIC (39)||Death, MI, ST, stroke, or urgent TVR||Superiority not shown||6.0||4.0||63|
|SECURITY (6 vs. 12 mo) (20)||2014||Stopped after 1,399 enrolled of 2,740 planned||Cardiac death, MI, ST, or stroke||Noninferiority confirmed||4.5||4.5||100|
|ITALIC (6 vs. 24 mo) (21)||2015||Stopped after 2,031 enrolled of 2,475 planned||Death, MI, urgent TVR, stroke, or major bleeding||Noninferiority confirmed||3.0||1.5||100|
|ISAR-SAFE (6 vs. 12 mo) (22)||2015||Stopped after 4,005 enrolled of 6,000 planned||Death, MI, ST, stroke, or TIMI major bleed||Noninferiority confirmed||10.0||1.5||72|
|DAPT (12 vs. 30 mo) (23)||2015||Enrollment completed||Coprimary: ST and MACCE||Superiority shown||0.5/2.9||0.5/2.4||59|
|OPTIDUAL (12 vs. 48 mo) (24)||2015||Stopped after 1,385 enrolled of 1,966 planned||Death, MI, stroke, or major bleed||Superiority not shown||7.0||7.5||59|
ARCTIC indicates Assessment by a Double Randomisation of a Conventional Antiplatelet Strategy Versus a Monitoring-Guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption Versus Continuation 1 Year After Stenting; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; DES-LATE, Optimal Duration of Clopidogrel Therapy With Drug Eluting Stents to Reduce Late Coronary Arterial Thrombotic Events; EXCELLENT, Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting; ISAR-SAFE, Intracoronary Stenting and Antithrombotic Regimen: Safety and Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting; ITALIC, Is There A Life for DES After Discontinuation of Clopidogrel; MACCE, major adverse cardiac and cerebrovascular events (death, MI, or stroke); MI, myocardial infarction; NACCE, net adverse cardiac and cerebrovascular events (death, MI, stroke, or major bleeding); OPTIDUAL, Optimal Dual Antiplatelet Therapy; OPTIMIZE, Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice; PRODIGY, Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia; RCT, randomized controlled trial; REAL-LATE, REAL-world patients treated with drug-eluting stent implantation and Late coronary Arterial Thrombotic Events; RESET, Real Safety and Efficacy of 3-month Dual Antiplatelet Therapy Following Endeavor Zotarolimus-Eluting Stent Implantation; revasc, revascularization; SECURITY, Second Generation Drug-Eluting Stent Implantation Followed by Six- Versus Twelve-Month Dual Antiplatelet Therapy; ST, stent thrombosis; TIMI, Thrombolysis In Myocardial Infarction; TVF, target-vessel failure; TVR, target-vessel revascularization; and ZEST-LATE, Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or Paclitaxel-Eluting Stent Implantation for Coronary Lesions-Late coronary Arterial Thrombotic Events.
↵∗ Year of initial publication.